Jane Huang - Net Worth and Insider Trading

Jane Huang Net Worth

The estimated net worth of Jane Huang is at least $33 Million dollars as of 2025-04-11. Jane Huang is the CMO, Hematology of BeiGene Ltd and owns about 160,055 shares of BeiGene Ltd (ONC) stock worth over $33 Million. Jane Huang is also the President, CMO of Prelude Therapeutics Inc and owns about 24,220 shares of Prelude Therapeutics Inc (PRLD) stock worth over $15,544. Details can be seen in Jane Huang's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Jane Huang has not made any transactions after 2023-04-06 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Jane Huang

Jane Huang Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Jane Huang owns 3 companies in total, including BeiGene Ltd (ONC) , Protara Therapeutics Inc (TARA) , and Prelude Therapeutics Inc (PRLD) .

Click here to see the complete history of Jane Huang’s form 4 insider trades.

Insider Ownership Summary of Jane Huang

Ticker	Comapny	Transaction Date	Type of Owner
ONC	BeiGene Ltd	2021-12-14	CMO & Hematology
TARA	Protara Therapeutics Inc	2021-06-09	director
PRLD	Prelude Therapeutics Inc	2023-04-06	President & CMO

Jane Huang Latest Holdings Summary

Jane Huang currently owns a total of 2 stocks. Among these stocks, Jane Huang owns 160,055 shares of BeiGene Ltd (ONC) as of December 14, 2021, with a value of $33 Million and a weighting of 99.95%. Jane Huang also owns 24,220 shares of Prelude Therapeutics Inc (PRLD) as of April 6, 2023, with a value of $15,544 and a weighting of 0.05%.

Latest Holdings of Jane Huang

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
ONC	BeiGene Ltd	2021-12-14	160,055	208.11	33,309,046
PRLD	Prelude Therapeutics Inc	2023-04-06	24,220	0.64	15,544

Holding Weightings of Jane Huang

Jane Huang Form 4 Trading Tracker

According to the SEC Form 4 filings, Jane Huang has made a total of 28 transactions in BeiGene Ltd (ONC) over the past 5 years, including 0 buys and 28 sells. The most-recent trade in BeiGene Ltd is the sale of 1,500 shares on December 14, 2021, which brought Jane Huang around $417,210.

According to the SEC Form 4 filings, Jane Huang has made a total of 1 transactions in Prelude Therapeutics Inc (PRLD) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Prelude Therapeutics Inc is the sale of 13,280 shares on April 6, 2023, which brought Jane Huang around $81,274.

Insider Trading History of Jane Huang

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Jane Huang Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Jane Huang Ownership Network

Ownership Network List of Jane Huang

No Data

Ownership Network Relation of Jane Huang

Jane Huang Owned Company Details

What does BeiGene Ltd do?

Who are the key executives at BeiGene Ltd?

Jane Huang is the CMO & Hematology of BeiGene Ltd. Other key executives at BeiGene Ltd include director & 10 percent owner Baker Bros. Advisors Lp , 10 percent owner Hillhouse Capital Advisors, Ltd. , and director & 10 percent owner & Chief Executive Office John Oyler .

BeiGene Ltd (ONC) Insider Trades Summary

Over the past 18 months, Jane Huang made no insider transaction in BeiGene Ltd (ONC). Other recent insider transactions involving BeiGene Ltd (ONC) include a net sale of 361,154 shares made by John Oyler , a net sale of 171,032 shares made by Xiaobin Wu , and a net sale of 4,882 shares made by Chan Henry Lee .

In summary, during the past 3 months, insiders sold 1,178,666 shares of BeiGene Ltd (ONC) in total and bought 0 shares, with a net sale of 1,178,666 shares. During the past 18 months, 21,397,509 shares of BeiGene Ltd (ONC) were sold and 0 shares were bought by its insiders, resulting in a net sale of 21,397,509 shares.

BeiGene Ltd (ONC)'s detailed insider trading history can be found in Insider Trading Tracker table.

BeiGene Ltd Insider Transactions

No Available Data

What does Protara Therapeutics Inc do?

Who are the key executives at Protara Therapeutics Inc?

Jane Huang is the director of Protara Therapeutics Inc. Other key executives at Protara Therapeutics Inc include Sr. Vice President & Research Jacqueline Zummo , 10 percent owner Opaleye Management Inc. , and Chief Financial Officer Patrick Fabbio .

Protara Therapeutics Inc (TARA) Insider Trades Summary

Over the past 18 months, Jane Huang made no insider transaction in Protara Therapeutics Inc (TARA). Other recent insider transactions involving Protara Therapeutics Inc (TARA) include a net sale of 703,460 shares made by Opaleye Management Inc. , and a net sale of 21,224 shares made by Jacqueline Zummo .

In summary, during the past 3 months, insiders sold 21,224 shares of Protara Therapeutics Inc (TARA) in total and bought 0 shares, with a net sale of 21,224 shares. During the past 18 months, 724,684 shares of Protara Therapeutics Inc (TARA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 724,684 shares.

Protara Therapeutics Inc (TARA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Protara Therapeutics Inc Insider Transactions

No Available Data

What does Prelude Therapeutics Inc do?

Who are the key executives at Prelude Therapeutics Inc?

Jane Huang is the President & CMO of Prelude Therapeutics Inc. Other key executives at Prelude Therapeutics Inc include EVP & Head of Chemistry Andrew Combs , director & President & CEO Krishna Vaddi , and Chief Legal Counsel & Corp Sec. Bryant David Lim .

Prelude Therapeutics Inc (PRLD) Insider Trades Summary

Over the past 18 months, Jane Huang made no insider transaction in Prelude Therapeutics Inc (PRLD). Other recent insider transactions involving Prelude Therapeutics Inc (PRLD) include a net purchase of 953,909 shares made by Krishna Vaddi , a net purchase of 163,075 shares made by Andrew Combs , and a net purchase of 25,000 shares made by Bryant David Lim .

In summary, during the past 3 months, insiders sold 0 shares of Prelude Therapeutics Inc (PRLD) in total and bought 932,021 shares, with a net purchase of 932,021 shares. During the past 18 months, 0 shares of Prelude Therapeutics Inc (PRLD) were sold and 1,141,984 shares were bought by its insiders, resulting in a net purchase of 1,141,984 shares.

Prelude Therapeutics Inc (PRLD)'s detailed insider trading history can be found in Insider Trading Tracker table.

Prelude Therapeutics Inc Insider Transactions

No Available Data

Jane Huang Mailing Address

Above is the net worth, insider trading, and ownership report for Jane Huang. Based on the public information released on the U.S. Securities and Exchange Commission (SEC) website, Jane Huang's mailing address is: Grand Cayman E9 Ky1-1108.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.